Acetylated and Related Analogues of Chicoric Acid as HIV Integrase Inhibitors
Description of Invention:
The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). Drug-resistance is a critical factor contributing to the gradual loss of clinical benefit to treatments for HIV infection. Accordingly, combination therapies have further evolved to address the mutating resistance of HIV. However, there has been great concern regarding the apparent growing resistance of HIV strains to current therapies.
Chicoric acid has been found to have potential in HIV therapies. The subject invention provides for new chicoric acid analogues and derivatives that inhibit HIV-1 integrase, as well as improved synthetic methods for enantiomers of chicoric acid itself as well as its analogues and derivatives. Also provided are methods for inhibiting the replication of HIV-1 either alone or in combination therapies.
Inventors:
Terrence R. Burke Jr. et al. (NCI)
Patent Status:
DHHS Reference No. E-076-1999/0 -- Research Tool
Licensing Status: Available for licensing under a Biological Materials License
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
